A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non‐specialist needs to know
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Non‐alcoholic fatty liver disease (NAFLD) has a rapidly rising prevalence worldwide and is the most common cause of liver disease in developed countries. In this article, we discuss the spectrum of disease of NAFLD with a focus on the earlier spectrum of the disease that is commonly encountered by non‐specialists, as well as the hepatic and extra‐hepatic associations of the disease. We discuss in detail the two common presentations of NAFLD, incidentally detected hepatic steatosis and asymptomatic raised liver enzymes, and provide an algorithm for management and continued to follow up for these patients. Considerations for the management of cardiovascular comorbidities in these patients are also discussed. Finally, we cover the topic of screening for NAFLD in high‐risk populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“Non-alcoholic fatty liver disease (NAFLD) is a fast becoming the most common liver disease worldwide.(1) The progressive increase in the”
BackgroundCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206 · cited 3×
“Patients with NAFLD may mani- fest with a reduced estimated glomerular filtration rate, or the presence of albuminuria.59–61 These appear to correlate positively with the presence of NASH as well as the severity of liver fibrosis, and improvements in liver histology were associated with an improvement in the CKD.62,63…”
BackgroundEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 2×
“Some patients may have an increased ALP.13 It should however be remembered that ele- vated liver enzymes are not specific for NAFLD and all patients with elevated liver enzymes should be evaluated for viral hepatitis, alcohol use or drug-induced liver injury because the consequences of missing the diagnosis may be fat…”
BackgroundPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 3×
“logical improvements in the liver in patients with NASH, the more advanced form of NAFLD, for patients with and without T2DM.(93,109)”
BackgroundSelf-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Garcia‐Tsao, G., Abraldes, J. G., Berzigotti, A., & Bosch, J. (2017) · Hepatology · doi:10.1002/hep.28906 · Cited by 2,154
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 3×
“GLP-1 RAs have demonstrated improvement in cardiovascular and all-cause mortality in high-risk patients with type 2 diabetes.104 They have demonstrated evidence of reducing heart failure and pro- gression of chronic kidney disease (CKD) in certain patients, and are associated with significant weight loss.105 In additi…”
BackgroundSelf-citationProfound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Treatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
Bray, G. A., Frühbeck, G., Ryan, D. H., & Wilding, J. P. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00271-3 · Cited by 1,036
Younossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802
Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease
Kanwal, F., Kramer, J. R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson, P. A., Li, L., Desiderio, R., Thrift, A. P., Asch, S. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.024 · Cited by 795 · cited 1×
“However, up to 20% of patients with NAFLD-related HCC develop HCC before the onset of cirrhosis.(32) Patients with NAFLDrelated HCC are diagnosed at a later tumour stage, have worse”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Insulin resistance in nonobese patients with polycystic ovarian disease
CHANG, R. J., NAKAMURA, R. M., JUDD, H. L., & KAPLAN, S. A. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-2-356 · Cited by 704
Piscaglia, F., Svegliati‐Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., Bellentani, S., & on behalf of the HCC‐NAFLD Italian Study Group (2016) · Hepatology · doi:10.1002/hep.28368 · Cited by 604
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503
Mantovani, A., Petracca, G., Beatrice, G., Tilg, H., Byrne, C. D., & Targher, G. (2021) · Gut · doi:10.1136/gutjnl-2020-322572 · Cited by 481 · cited 2×
“ing incident diabetes, with a higher risk seen in those with more severe disease.(40) Conversely, patients with diabetes are at increased risk of developing NAFLD, with a higher prevalence in patients with a higher HbA1c.”
BackgroundWeight Regain in U.S. Adults Who Experienced Substantial Weight Loss, 1999–2002
Weiss, E. C., Galuska, D. A., Kettel Khan, L., Gillespie, C., & Serdula, M. K. (2007) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2007.02.040 · Cited by 307 · cited 1×
“the required weight loss, and even among those who do, a large proportion return to their baseline weight within 5 years.(101) Changing”
BackgroundDiagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage
Siddiqui, M. S., Yamada, G., Vuppalanchi, R., Van Natta, M., Loomba, R., Guy, C., Brandman, D., Tonascia, J., Chalasani, N., Neuschwander-Tetri, B., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.12.031 · Cited by 272
Self-citationKumarendran, B., O’Reilly, M. W., Manolopoulos, K. N., Toulis, K. A., Gokhale, K. M., Sitch, A. J., Wijeyaratne, C. N., Coomarasamy, A., Arlt, W., & Nirantharakumar, K. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002542 · Cited by 206
Bril, F., Kalavalapalli, S., Clark, V. C., Lomonaco, R., Soldevila-Pico, C., Liu, I.-C., Orsak, B., Tio, F., & Cusi, K. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.001 · Cited by 199 · cited 2×
“logical improvements in the liver in patients with NASH, the more advanced form of NAFLD, for patients with and without T2DM.(93,109)”
BackgroundMost, J., Gilmore, L. A., Smith, S. R., Han, H., Ravussin, E., & Redman, L. M. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00261.2017 · Cited by 117 · cited 1×
“Losing weight by dieting and limiting caloric intake can improve the liver fat as well as the associated cardiovascular risk factors of these patients.(97) A proposed intake of 500 kcal/day below energy requirements has been shown to help achieve weight loss.”
BackgroundDepression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
Colognesi, M., Gabbia, D., & De Martin, S. (2020) · Biomedicines · doi:10.3390/biomedicines8070229 · Cited by 98
Xiao, J., Lim, L. K. E., Ng, C. H., Tan, D. J. H., Lim, W. H., Ho, C. S. H., Tan, E. X. X., Sanyal, A. J., & Muthiah, M. D. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.691696 · Cited by 94 · cited 2×
“In addition, the psychological impairments associated with NAFLD is likely to worsen the results with lifestyle interventions.(70)”
BackgroundResultSelf-citationThe association of nonalcoholic steatohepatitis and obstructive sleep apnea
Asfari, M. M., Niyazi, F., Lopez, R., Dasarathy, S., & McCullough, A. J. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000973 · Cited by 25 · cited 1×
“Obstructive sleep apnoea (OSA) has been associated with NASH, with OSA patients being three times more likely to have NASH after adjusting for metabolic risk factors.(79) The presence of OSA correlated with steatosis grade, lobular inflammation, NAS score, and fibrosis stage.”
Background
Cited by
Quek, J., Chan, K. E., Wong, Z. Y., Tan, C., Tan, B., Lim, W. H., Tan, D. J. H., Tang, A. S. P., Tay, P., Xiao, J., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00317-x · Cited by 749
Self-citationEn Li Cho, E., Ang, C. Z., Quek, J., Fu, C. E., Lim, L. K. E., Heng, Z. E. Q., Tan, D. J. H., Lim, W. H., Yong, J. N., Zeng, R., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-330110 · Cited by 380
Self-citationChan, K. E., Koh, T. J. L., Tang, A. S. P., Quek, J., Yong, J. N., Tay, P., Tan, D. J. H., Lim, W. H., Lin, S. Y., Huang, D., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac321 · Cited by 315
Self-citationBile Acid Receptors and the Gut–Liver Axis in Nonalcoholic Fatty Liver Disease
Xue, R., Su, L., Lai, S., Wang, Y., Zhao, D., Fan, J., Chen, W., Hylemon, P. B., & Zhou, H. (2021) · Cells · doi:10.3390/cells10112806 · Cited by 95
Tan, B., Pan, X.-H., Chew, H. S. J., Goh, R. S. J., Lin, C., Anand, V. V., Lee, E. C. Z., Chan, K. E., Kong, G., Ong, C. E. Y., et al. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01321-5 · Cited by 83
Self-citation
Metadata
- Authors
- Muthiah, M. D., Cheng Han, N., & Sanyal, A. J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2021-09-14
- Volume
- 24
- Issue
- S2
- Pages
- 3-14
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W3187380242
- Cited by
- 108
- References
- 31
- FWCI
- 12.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.